Dr. Saeed Rafii on Atezolizumab/ Nab-paclitaxel in TNBC
Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute United Kingdom, discusses a study evaluating the safety and clinical activity of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (TNBC).
Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute United Kingdom, discusses a study evaluating the safety and clinical activity of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (TNBC).
There were 24 evaluable patients in the trial, says Rafii. The confirmed response rate in TNBC was 41.7%. Investigators noted that patients who had received nab-paclitaxel and atezolizumab as a first-line treatment for metastatic TNBC had a higher response rate of 66.7%. However, this was based on a small cohort of 9 patients, explains Rafii.
There were significant hematologic toxicities seen in the study, including 40.1% of patients who developed a grade III neutropenia, 9% who developed a grade III thrombocytopenia, and 6% who developed grade II anemia.
<<<
